Medivation Receives Consensus Recommendation of “Hold” from Brokerages (NASDAQ:MDVN)
Shares of Medivation (NASDAQ:MDVN) have received an average recommendation of “Hold” from the twenty-one ratings firms that are presently covering the stock, AnalystRatings.NET reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $90.69.
Medivation (NASDAQ:MDVN) traded down 0.66% during mid-day trading on Friday, hitting $75.36. 92,816 shares of the company’s stock traded hands. Medivation has a one year low of $44.51 and a one year high of $88.20. The stock has a 50-day moving average of $65.56 and a 200-day moving average of $68.15. The company’s market cap is $5.767 billion. Medivation also was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 5,107,671 shares, an increase of 36.3% from the April 30th total of 3,746,145 shares. Based on an average daily trading volume, of 1,325,146 shares, the days-to-cover ratio is currently 3.9 days. Approximately 6.9% of the shares of the company are short sold.
Medivation (NASDAQ:MDVN) last released its earnings data on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.09. The company had revenue of $87.19 million for the quarter, compared to the consensus estimate of $94.64 million. During the same quarter in the prior year, the company posted ($0.36) earnings per share. The company’s quarterly revenue was up 88.9% on a year-over-year basis. Analysts expect that Medivation will post $1.35 EPS for the current fiscal year.
MDVN has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note on Monday, May 26th. They now have a $72.00 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Medivation in a research note on Thursday, May 22nd. They set a “buy” rating and a $81.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Medivation from a “sell” rating to a “hold” rating in a research note on Wednesday, May 14th.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.